Bibliography
- Silberstein SD , LiptonRB: Epidemiology of migraine.Neuroepidemiology12,179–194 (1993).
- Stewart WF , LiptonRB, CelentanoDD, ReedML: Prevalence of migraine headache in the United States – relation to age, race, income, and other sociodemographic factors.JAMA267,64–69 (1992).
- Russel MB , RasmussenBK, Thornvaldesen P, Olesen J: Prevalence and sex ratio of the subtypes of migraine. Int. J. Epidem.24,612–618 (1995).
- Rasmussen BK : Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain53,65–72 (1993).
- Hering R , KurzitzkyA: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia12,81–84 (1992).
- Freitag F , CollinsS, CarlsonH et al.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology58,1652–1659 (2002).
- van der Kuy P , LohmanJ: A quantification of the placebo response in migraine prophylaxis.Cephalalgia22(4),265–270 (2002).
- Jensen R , BrinckT, OlesenJ: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.Neurology44,647–651 (1994).
- Kaniecki RG : A comparision of divalproex with propranolol and placebo for the prophylaxis of migraine without aura.Arch. Neurol.54,1141–1145 (1997).
- Klapper J : On behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study.Cephalalgia17,103–108 (1997).
- Garnett WR : Clinical pharmacology of topiramate: a review.Epilepsia40(Suppl.1),S61–S65 (2000).
- Johannessen SI : Pharmacokinetic and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.Epilepsia38(Suppl. 1),S18–S23 (1997).
- Perucca E : Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.Epilepsia37(Suppl. 2),S8–S13 (1996).
- Doose DR , WalkerSA, GisclonLG, Nayak RK: Single-dose pharmacokinetics and effect of food on the bioavaiability of topiramate, a novel antielipeltic drug. J. Clin. Pharmacol.36,884–891 (1996).
- Mathew NT , SaperJR, SilbersteinSD et al.: Migraine prophylaxis with divalproex. Arch. Neurol.52,281–286 (1995).
- Edwards KR , GlantzMJ, NortonJA et al.: Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients. Cephalalgia20,316 (2000).
- Storey JR , CalderCS, HartDE, PotterDL: Topiramate in migraine prevention: a double-blind, placebo-controlled study.Headache41,968–975 (2001).
- Silberstein SD , NetoW, SchmittJ, Jacobs D: MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol.61(4),490–495 (2004).
- Brandes JL , SaperJR, DiamondM et al.: MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA291(8),965–973 (2004).
- Diener HC , Tfelt-HansenP, DahlofC et al.: MIGR-003 Study Group. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J. Neurol.251(8),943–950 (2004).
- Pascual J , Sanchez del Rio M, Mateos V et al.: Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurologia (7),364–367 (2003).
- Láinez MJ , PascualJ, PascualAM, Santonja JM, Ponz A, Salvador A: Topiramate in the prophylactic treatment of cluster headache. Headache43(7),784–789 (2003).